Multispecialty - GSK
Multispecialty
Status:
EnrollingClinicalTrials.gov:
NCT05878717A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)